Content

Welcome to the CJU website » LOG IN

HOW I DO IT


First Prev Page 1 of 12 Next Last
  • How I Do It: Cost-effective 3D printed models for renal masses

    Scott Reilly E., Singh Abhay, Quinn Andrea, Boyd Kaitlyn, Lallas D. Costas Sidney Kimmel Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, USA

    3D printing has been growing in many surgical fields including Urology. The primary use has been to print kidneys with tumors to better understand anatomy and to assist with surgical planning and education. Previous studies that utilized 3D printing of kidneys for partial nephrectomies have been limited by the cost and complexity of model creation, rendering them highly impractical to be used on a routine basis. Using a simpler and more cost-effective design and materials allow the 3D kidney models to be used in a wider range and number of patients. We describe our streamlined process to create 3D kidney models costing $30 on average and we believe this process can be repeated by others.

    Oct 2021 (Vol. 28, Issue 5 , Page 10874)
  • How I Do It: Technical report on surgically-initiated rectus sheath catheter using catheter-over-needle assembly

    Ip H. Y. Vivian, Khurana Jaasmit, Jacobsen Niels-Erik, Fairey S. Adrian, Sondekoppam V. Rakesh Department of Anesthesiology and Pain Medicine, University of Alberta Hospital, Edmonton, Alberta, Canada

    Development of chronic postsurgical pain following major abdominal or pelvic surgeries is increasingly recognized. Multimodal analgesia including regional anesthesia such as rectus sheath block is growing in popularity. While the literature mainly describes ultrasound-guided rectus sheath blocks, there are many advantages to surgically-initiated rectus sheath catheter performed at the end of surgery. In this technical description, we describe the rationale and technique of surgical insertion of rectus sheath catheters following major urologic surgery with midline incision which is routinely performed by urologists at our institution. Furthermore, we would like to highlight the type of catheter used during rectus sheath catheter insertion, namely the catheter-over-needle assembly. It is simple to insert while minimizes complications such as local anesthetic leakage at the insertion site causing dressing disruption and premature catheter dislodgement, as the catheter-over-needle assembly fits snugly with the skin after insertion.

    Oct 2021 (Vol. 28, Issue 5 , Page 10871)
  • Robotic intracorporeal orthotopic neobladder in the supine Trendelenburg position: a stepwise approach

    Bhattu S. Amit, Ritch R. Chad, Jahromi Mona, Banerjee Indraneel, Gonzalgo L. Mark, MD Department of Urology, University of Miami Miller School of Medicine, Miami, Florida, USA

    Robotic radical cystectomy with urinary diversion has become increasingly utilized for the surgical management of bladder cancer. Orthotopic neobladder reconstruction is still performed worldwide primarily via an extracorporeal approach because of the difficulty associated with robotic intracorporeal reconstruction. The objective of this article is to demonstrate a stepwise approach for robotic intracorporeal neobladder in a standardized manner that adheres to the principles of open surgery.

    Keywords: robotics, intracorporeal, neobladder, supine, patient positioning, orthotopic, table motion,

    Aug 2021 (Vol. 28, Issue 4 , Page 10794)
  • How I Do It: Temporarily Implanted Nitinol Device (iTind)

    Elterman Dean, Gao Bruce, Zorn C. Kevin, Bhojani Naeem, Chughtai Bilal, MD Division of Urology, Department of Surgery, University of Toronto, Toronto, Ontario, Canada

    Benign prostatic hyperplasia is a common and progressive disease affecting aging men which has a significant impact on quality of life. The second-generation Temporarily Implanted Nitinol Device (iTind) is an FDA approved temporary prostatic urethral device which can be deployed using standard flexible cystoscopy without sedation or general anesthesia. The device is left in-situ for 5 to 7 days and is then entirely removed in the office, using an open-ended silicone catheter. Prospective, randomized data indicate that iTind has favorable functional and sexual patient outcomes. Readers will familiarize themselves with iTind, significant historical studies and the technique for deploying iTind using a flexible cystoscope in the office setting.

    Keywords: prostate, BPH, TMIST, iTind,

    Aug 2021 (Vol. 28, Issue 4 , Page 10788)
  • Using darolutamide in advanced prostate cancer: How I Do It

    Hamilton Joelle, MD Urology Centers of Alabama, Homewood, Alabama, USA

    Darolutamide is a nonsteroidal androgen inhibitor FDA approved for the treatment of castration-resistant non-metastatic prostate cancer (nmCRPC). After decades of offering androgen deprivation therapy (ADT) alone or first-generation androgen receptor blockers for patients whose PSA was rising despite castrate levels of testosterone, there are now three different treatment options to add to ADT. These include apalutamide approved in February 2018, enzalutamide FDA approved in June 2018, and darolutamide approved July 2019. Each of these androgen receptor pathway blockers, when added to ADT or surgical orchiectomy, prolongs metastasis-free-survival (MFS) and median survival (MS). This paper focuses on the use of the newest approved agent in this class, darololutmide.

    Keywords: prostate cancer, castrate-resistant, non-metastatic disease, antiandrogen, darolutamide,

    Jun 2021 (Vol. 28, Issue 3 , Page 10673)
First Prev Page 1 of 12 Next Last

Current Issue

October 2021, Vol.28 No.5
canadian journal of urology